The Promise Of Numab's Multispecific Antibodies
CHF100m Raised In Series C Financing
Swiss biotech Numab Therapeutics has raised an oversubscribed series C financing of CHF100m to accelerate the development of its multispecific antibodies, from investors attracted by the company’s thoughtful approach to developing its technology.
